2025 Q4 -tulosraportti
Vain PDF
4 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 6 492 | - | - | ||
| 1 600 | - | - | ||
| 4 500 | - | - | ||
| 7 408 | - | - | ||
| 5 000 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·24 min sittenBennyz is right: People are still staring at the Oslo ticker as if it tells them what Circio is. It doesn't. Circio is listed in Oslo, but the case is not decided in the local pond here at home. It is decided by data, technology, and partner relevance in an international market that cares about completely different things than daily penny fluctuations. If circVec continues to deliver, this is not a “small Norwegian biotech case”. Then it is a platform company in a global race for next-generation RNA technology. That's why so many read the stock wrong. They follow the price. They should follow the value of what is being built. Oslo is just the screen you see the stock on. That's not where the case is decided.
·40 min sittenTHE GLOBAL MACHINERY: Why the ticker symbol on Oslo Børs is an illusion 🌍🧬 There is one massive misunderstanding that affects far too many of the small investors in here: They think they have bought shares in a "small Norwegian biotech company". Wrong. You have bought into an international machinery that just coincidentally uses Oslo Børs as a financial showcase. Let's take a look behind the scenes at how this company is actually structured. Because if you think this is a local hobby project in a back room in Norway, you haven't been paying attention. The truth is that the very heart of the operation – the hard-hitting science and the main lab – is located in Sweden. Management and key personnel have deep roots towards Denmark, which coincidentally is one of Europe's absolutely most powerful biotech nations. Oslo Børs is literally just the cash register. The real work happens in international biotech hubs where the infrastructure, network, and capital are actually located. Then you have the team they are building. If you take a look at the payroll, you'll find almost as many nationalities as there are employees. Why? Because when developing a circular RNA platform that can potentially upgrade the entire modern pharmaceutical industry, you cannot settle for recruiting locally. The company systematically headhunts the sharpest minds within its extremely narrow, complex niche from all over the world. Think about it for a second: These are world-class scientists. Do you think such people uproot their lives and move across borders for a mediocre project they don't believe in? Absolutely not. They do it because they have seen the data, they understand the circVec-platform, and they know they are working on a potential medical quantum leap. How massive is this market? Let's look at the cold facts: In 2022, mRNA medicine alone generated over 50 billion dollars in revenue. RNA technology literally took the top of the pharmaceutical food chain and became the most lucrative tool in modern medicine. And remember: That was with Version 1.0 (linear mRNA). Circio is building Version 2.0. Oslo Børs is a duck pond for deep biotech investment. That is precisely why our stock can swing wildly on microscopic volumes – there is a lack of liquidity to absorb the noise from local day traders playing shop. While they argue over pennies, the global apparatus is building the foundation for the next generation. Out in the real world – where Big Pharma is looking for the next generation of RNA delivery technology – they care absolutely nothing about the noise on Nordnet. They care about patents, the team's expertise, and international partnerships. Understand the architecture of what you own. We are not a Norwegian company structured for Oslo. We are a global player structured for the world. The stock exchange opens tomorrow. Let the small investors argue about penny fluctuations. We know exactly what we own. ♟️🧱🍷
·26 min sittenWell described. It would not have been possible to develop this in Norway when one is dependent on internajonal expertise. Option taxation and exit tax would have put employees in a tax predicament if the options had become valuable. C would have had to disclose this before the employees and then they would not have come. Arbeidstilatelser take many months and are business-hostile. Therefore, top expertise is recruited to Swedish and Danish technology companies.
·2 t sittenDoes anyone have any info on how long HØSE AS has been a shareholder?·46 min sittenHøse AS has been a large and the largest shareholder since 2022/2023 and has significantly supported and contributed to the financing of the company. In the annual report for 2021, they were not on the list of the 20 largest. In the 2022 annual report from April 2023, they were the largest shareholder with 3.4% of the shares. Høse AS has been an exemplary owner. They are industry builders and understand that building solid technology can take time. I wish them all the gains.
·3 t sitten
·4 t sittenCoffee cup and reading on the forum while we wait for the market open on Monday. Completely meaningless poll, but still interesting. What percentage of your portfolio is invested in Circio?39 ääntä 2 päivää 19 tuntia jäljelläLiity Sharevilleen osallistuaksesi kyselyyn
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
4 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·24 min sittenBennyz is right: People are still staring at the Oslo ticker as if it tells them what Circio is. It doesn't. Circio is listed in Oslo, but the case is not decided in the local pond here at home. It is decided by data, technology, and partner relevance in an international market that cares about completely different things than daily penny fluctuations. If circVec continues to deliver, this is not a “small Norwegian biotech case”. Then it is a platform company in a global race for next-generation RNA technology. That's why so many read the stock wrong. They follow the price. They should follow the value of what is being built. Oslo is just the screen you see the stock on. That's not where the case is decided.
- ·40 min sittenTHE GLOBAL MACHINERY: Why the ticker symbol on Oslo Børs is an illusion 🌍🧬 There is one massive misunderstanding that affects far too many of the small investors in here: They think they have bought shares in a "small Norwegian biotech company". Wrong. You have bought into an international machinery that just coincidentally uses Oslo Børs as a financial showcase. Let's take a look behind the scenes at how this company is actually structured. Because if you think this is a local hobby project in a back room in Norway, you haven't been paying attention. The truth is that the very heart of the operation – the hard-hitting science and the main lab – is located in Sweden. Management and key personnel have deep roots towards Denmark, which coincidentally is one of Europe's absolutely most powerful biotech nations. Oslo Børs is literally just the cash register. The real work happens in international biotech hubs where the infrastructure, network, and capital are actually located. Then you have the team they are building. If you take a look at the payroll, you'll find almost as many nationalities as there are employees. Why? Because when developing a circular RNA platform that can potentially upgrade the entire modern pharmaceutical industry, you cannot settle for recruiting locally. The company systematically headhunts the sharpest minds within its extremely narrow, complex niche from all over the world. Think about it for a second: These are world-class scientists. Do you think such people uproot their lives and move across borders for a mediocre project they don't believe in? Absolutely not. They do it because they have seen the data, they understand the circVec-platform, and they know they are working on a potential medical quantum leap. How massive is this market? Let's look at the cold facts: In 2022, mRNA medicine alone generated over 50 billion dollars in revenue. RNA technology literally took the top of the pharmaceutical food chain and became the most lucrative tool in modern medicine. And remember: That was with Version 1.0 (linear mRNA). Circio is building Version 2.0. Oslo Børs is a duck pond for deep biotech investment. That is precisely why our stock can swing wildly on microscopic volumes – there is a lack of liquidity to absorb the noise from local day traders playing shop. While they argue over pennies, the global apparatus is building the foundation for the next generation. Out in the real world – where Big Pharma is looking for the next generation of RNA delivery technology – they care absolutely nothing about the noise on Nordnet. They care about patents, the team's expertise, and international partnerships. Understand the architecture of what you own. We are not a Norwegian company structured for Oslo. We are a global player structured for the world. The stock exchange opens tomorrow. Let the small investors argue about penny fluctuations. We know exactly what we own. ♟️🧱🍷·26 min sittenWell described. It would not have been possible to develop this in Norway when one is dependent on internajonal expertise. Option taxation and exit tax would have put employees in a tax predicament if the options had become valuable. C would have had to disclose this before the employees and then they would not have come. Arbeidstilatelser take many months and are business-hostile. Therefore, top expertise is recruited to Swedish and Danish technology companies.
- ·2 t sittenDoes anyone have any info on how long HØSE AS has been a shareholder?·46 min sittenHøse AS has been a large and the largest shareholder since 2022/2023 and has significantly supported and contributed to the financing of the company. In the annual report for 2021, they were not on the list of the 20 largest. In the 2022 annual report from April 2023, they were the largest shareholder with 3.4% of the shares. Høse AS has been an exemplary owner. They are industry builders and understand that building solid technology can take time. I wish them all the gains.
- ·3 t sitten
- ·4 t sittenCoffee cup and reading on the forum while we wait for the market open on Monday. Completely meaningless poll, but still interesting. What percentage of your portfolio is invested in Circio?39 ääntä 2 päivää 19 tuntia jäljelläLiity Sharevilleen osallistuaksesi kyselyyn
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 6 492 | - | - | ||
| 1 600 | - | - | ||
| 4 500 | - | - | ||
| 7 408 | - | - | ||
| 5 000 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
4 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·24 min sittenBennyz is right: People are still staring at the Oslo ticker as if it tells them what Circio is. It doesn't. Circio is listed in Oslo, but the case is not decided in the local pond here at home. It is decided by data, technology, and partner relevance in an international market that cares about completely different things than daily penny fluctuations. If circVec continues to deliver, this is not a “small Norwegian biotech case”. Then it is a platform company in a global race for next-generation RNA technology. That's why so many read the stock wrong. They follow the price. They should follow the value of what is being built. Oslo is just the screen you see the stock on. That's not where the case is decided.
- ·40 min sittenTHE GLOBAL MACHINERY: Why the ticker symbol on Oslo Børs is an illusion 🌍🧬 There is one massive misunderstanding that affects far too many of the small investors in here: They think they have bought shares in a "small Norwegian biotech company". Wrong. You have bought into an international machinery that just coincidentally uses Oslo Børs as a financial showcase. Let's take a look behind the scenes at how this company is actually structured. Because if you think this is a local hobby project in a back room in Norway, you haven't been paying attention. The truth is that the very heart of the operation – the hard-hitting science and the main lab – is located in Sweden. Management and key personnel have deep roots towards Denmark, which coincidentally is one of Europe's absolutely most powerful biotech nations. Oslo Børs is literally just the cash register. The real work happens in international biotech hubs where the infrastructure, network, and capital are actually located. Then you have the team they are building. If you take a look at the payroll, you'll find almost as many nationalities as there are employees. Why? Because when developing a circular RNA platform that can potentially upgrade the entire modern pharmaceutical industry, you cannot settle for recruiting locally. The company systematically headhunts the sharpest minds within its extremely narrow, complex niche from all over the world. Think about it for a second: These are world-class scientists. Do you think such people uproot their lives and move across borders for a mediocre project they don't believe in? Absolutely not. They do it because they have seen the data, they understand the circVec-platform, and they know they are working on a potential medical quantum leap. How massive is this market? Let's look at the cold facts: In 2022, mRNA medicine alone generated over 50 billion dollars in revenue. RNA technology literally took the top of the pharmaceutical food chain and became the most lucrative tool in modern medicine. And remember: That was with Version 1.0 (linear mRNA). Circio is building Version 2.0. Oslo Børs is a duck pond for deep biotech investment. That is precisely why our stock can swing wildly on microscopic volumes – there is a lack of liquidity to absorb the noise from local day traders playing shop. While they argue over pennies, the global apparatus is building the foundation for the next generation. Out in the real world – where Big Pharma is looking for the next generation of RNA delivery technology – they care absolutely nothing about the noise on Nordnet. They care about patents, the team's expertise, and international partnerships. Understand the architecture of what you own. We are not a Norwegian company structured for Oslo. We are a global player structured for the world. The stock exchange opens tomorrow. Let the small investors argue about penny fluctuations. We know exactly what we own. ♟️🧱🍷·26 min sittenWell described. It would not have been possible to develop this in Norway when one is dependent on internajonal expertise. Option taxation and exit tax would have put employees in a tax predicament if the options had become valuable. C would have had to disclose this before the employees and then they would not have come. Arbeidstilatelser take many months and are business-hostile. Therefore, top expertise is recruited to Swedish and Danish technology companies.
- ·2 t sittenDoes anyone have any info on how long HØSE AS has been a shareholder?·46 min sittenHøse AS has been a large and the largest shareholder since 2022/2023 and has significantly supported and contributed to the financing of the company. In the annual report for 2021, they were not on the list of the 20 largest. In the 2022 annual report from April 2023, they were the largest shareholder with 3.4% of the shares. Høse AS has been an exemplary owner. They are industry builders and understand that building solid technology can take time. I wish them all the gains.
- ·3 t sitten
- ·4 t sittenCoffee cup and reading on the forum while we wait for the market open on Monday. Completely meaningless poll, but still interesting. What percentage of your portfolio is invested in Circio?39 ääntä 2 päivää 19 tuntia jäljelläLiity Sharevilleen osallistuaksesi kyselyyn
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 6 492 | - | - | ||
| 1 600 | - | - | ||
| 4 500 | - | - | ||
| 7 408 | - | - | ||
| 5 000 | - | - |
Välittäjätilasto
Dataa ei löytynyt